Loading…
Loading…
DNA Advisors brings expertise in capital markets, strategic transactions, partnerships, and growth initiatives DNA Advisors brings expertise in capital markets, strategic transactions, partnerships, and growth initiatives
WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.
Kane Biotech Inc. (KNE:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 29, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces that on May 28, 2026 it granted an aggregate of 9,750,000 stock options (the "Options") to certain directors, officers, employees and consultants of the Company in accordance with the Company's third amended and restated stock option plan. Each Option is exercisable into one common share of the Company (a “Share”) at a price of $0.05 per Share, for a period of five years from the date of grant.
WINNIPEG, Manitoba, May 28, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its first quarter 2026 financial results.
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 26, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces that today it has increased the size of its previously announced non-brokered private placement offering (the “Offering”) of units of the Company (“Units”) from up to $1,000,000 to $1,160,000 and has subsequently completed such Offering. The increase in the size of the Offering was driven primarily by outside investor demand.
Case study presented highlighted clinical experience with revyve® in complex wound care Case study presented highlighted clinical experience with revyve® in complex wound care
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 07, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces its intention to undertake a non-brokered private placement offering (the “Offering”) of up to 20,000,000 units of the Company (“Units”) at a price of $0.05 per Unit for gross proceeds of up to $1,000,000. Each Unit shall be comprised of one common share of the Company (a “Share”) and one Share purchase warrant (a “Warrant”).
No recent filings indexed.